Symbicort SMART Satisfaction From Patient Perspective 2009

To characterize the level of asthma control and patient satisfaction amongst diagnosed asthma sufferers who are currently receiving Symbicort Maintenance and Reliever Therapy (SMART) in Malaysia.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Asthma Behavior Bronchial Diseases Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Lung Diseases Lung Diseases, Obstructive Personal Satisfaction Respiratory Hypersensitivity Respiratory Tract Diseases

Age range

18 year–59 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Research Site

Petaling Jaya, Selangor, Malaysia

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Have been prescribed Symbicort SMART (1 or 2 inhalation twice daily) by their Dr's for the past 3 months
Informed consent

Exclusion criteria

Symbicort SMART treatment < 3 months
Patients requiring short courses of oral steroids more than twice in a month

Treatment and study plan

Primary outcomes

Score level of Satisfaction in Asthma Treatment Questionnaire (SATQ)

Time frame: After 3 months on SMART - once
Score level of Asthma Control Test (ACT)

Time frame: After 3 months on SMART - once

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Important dates

Study start: 2009
Primary completion: 2010
Study completion: 2010
First posted: Jul 27, 2009
Registry last updated: Mar 18, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed